Aktienanalyse zu Acrivon Therapeutics, Inc. (ACRV)ACRVAcrivon Therapeutics, Inc.

Acrivon Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing precision oncology medicines. It uses its precision Generative Phosphoproteomics platform, Acrivon Predictive Precision Proteomics (AP3), to develop its pipeline of oncology drug candidates. Its lead candidate, ACR-368, is a selective small molecule inhibitor which targets CHK1 and CHK2 at sub single-digit nM and single-digit nM potency in intact cells, respectively, in a registrational Phase II trial across multiple solid tumor types. Using its AP3 platform, it has developed a predictive OncoSignature test for ACR-368, called ACR-368 OncoSignature, that can predict patient response to ACR-368 monotherapy and therefore improve the clinical overall response rate (ORR) and has the potential to enable drug development. Its preclinical program, ACR-2316, is advancing in investigational new drug-enabling studies. It is a novel, dual WEE1 and PKMYT1 inhibitor small molecule development candidate. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Acrivon Therapeutics Inc is currently not a strong buy due to its low price and negative earnings, but it shows potential for recovery. The current price is $1.61, significantly below the 52-week high of $3.56, indicating a 14.8% position within its 52-week range. However, the RSI is at 27.156, suggesting the stock is oversold, which could indicate a potential rebound. The forward P/E ratio is 0, reflecting uncertainty in future earnings, and the company has reported consistent losses, with a net income of -$19,042,000 in Q1 2026. The main risk is the ongoing negative earnings trend, as indicated by the EPS of -0.49 for Q1 2026, which may deter investors in the short term.